Lexicon Pharmaceuticals, Inc. (LXRX) Director Public Equities L.P. Invus Buys 575,946 Shares
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus bought 575,946 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average price of $9.64 per share, for a total transaction of $5,552,119.44. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded down $0.08 on Tuesday, hitting $9.73. The stock had a trading volume of 888,000 shares, compared to its average volume of 804,741. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09. Lexicon Pharmaceuticals, Inc. has a 12-month low of $8.07 and a 12-month high of $18.00.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The firm had revenue of $26.94 million during the quarter, compared to analyst estimates of $27.97 million. During the same quarter in the previous year, the firm earned ($0.35) EPS. Lexicon Pharmaceuticals’s quarterly revenue was down 2.8% compared to the same quarter last year. sell-side analysts forecast that Lexicon Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.
LXRX has been the subject of several recent analyst reports. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. BidaskClub lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Wedbush reaffirmed an “ourperform” rating and issued a $39.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $28.75.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.